NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The main goal of this study is to evaluate the anti-relapse prophylactic activity of
inoculating Natural Killer (NK) cells as consolidation therapy of acute myeloid leukemia in
paediatric patients with cytologic remission. The patients included have intermediate risk of
relapse and no indication for allogeneic hematopoietic stem cell transplantation.
After the standard induction and consolidation chemotherapy treatment, patients will receive
five days of fludarabine to try to kill any minimal residual disease and prevent NK cell
rejection. Two different NK cells infusions will be performed within one week (day 0 and 7).
Interleukin 2 (IL-2) will be administrated to increase the cytotoxic activity of NK cells.
Phase:
Phase 2
Details
Lead Sponsor:
Antonio Pérez Martínez Instituto de Investigación Hospital Universitario La Paz
Collaborators:
Fundación Mutua Madrileña Hospital Infantil Universitario Niño Jesús, Madrid, Spain Instituto de Investigación Hospital Universitario La Paz